Discover

HUMA
Humacyte, Inc.
0.71
1 x 0.51
3 x 0.92
bid
ask
+
0.04
5.56%
12:04 PM
timesize
Ytd-26.12%
1y-69.26%
0.70
day range
0.73
0.55
52 week range
2.84
Open0.70Prev Close0.67Low0.70High0.73Mkt Cap191.47M
Vol6.07MAvg Vol9.94MEPS-0.63P/EN/AForward P/E-5.41
Beta1.47Short Ratio6.37Inst. Own30.01%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg0.99200-d Avg1.161yr Est13.71

HUMA News

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
zacks.com
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change fro

Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
zacks.com
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
zacks.com
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

benzinga.com
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
zacks.com
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous tr

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
seekingalpha.com
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
zacks.com
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is r

benzinga.com
Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Va

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
globenewswire.com
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phas

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Bu

Why Is Humacyte Stock Falling Thursday?
benzinga.com
Why Is Humacyte Stock Falling Thursday?

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
globenewswire.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
Humacyte Commences Common Stock Offering; Terms Not Disclosed

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

Humacyte, Inc. Announces Proposed Public Offering of Common Stock
globenewswire.com
Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi

benzinga.com
Humacyte Announces Positive Interim Results From Phase Study Of Acellular Tissue Engineered Vessel I

The V012 clinical study is designed to demonstrate the efficacy and safety of the ATEV as a dialysis

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
globenewswire.com
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim An

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Ad

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
gurufocus.com
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Jun

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

benzinga.com
Benchmark Maintains Speculative Buy on Humacyte, Raises Price Target to $2

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and ra

Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
zacks.com
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

benzinga.com
HC Wainwright & Co. Reiterates Buy on Humacyte, Maintains $3 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Humacyte (NASDAQ:HUMA) with a B

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
globenewswire.com
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After C

- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually -  -

benzinga.com
Humacyte Says Symvess Is Now Under Contract With Strategic Acquisition Center Of US Department Of Ve

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
globenewswire.com
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

benzinga.com
TD Cowen Maintains Buy on Humacyte, Raises Price Target to $1.5

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price

benzinga.com
BTIG Maintains Buy on Humacyte, Lowers Price Target to $2

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Humacyte Q1 Earnings Call Highlights
marketbeat.com
Humacyte Q1 Earnings Call Highlights

Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a serie

Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
zacks.com
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus E

Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript

Earnings Scheduled For May 13, 2026
benzinga.com
Earnings Scheduled For May 13, 2026

benzinga.com
Humacyte Q1 EPS $(0.09) Beats $(0.11) Estimate, Sales $495.000K Miss $1.455M Estimate

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consens

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Offi

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
globenewswire.com
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership t

benzinga.com
Humacyte To Host KOL Event On April 28 To Discuss Unmet Need And Current Treatment Landscape For Hem

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

benzinga.com
Humacyte Realigns Ex-U.S. Rights To Symvess By Amending Its Distribution Deal With Fresenius Medical

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universa

benzinga.com
Barclays Maintains Overweight on Humacyte, Lowers Price Target to $1.5

Barclays analyst Matt Miksic maintains Humacyte (NASDAQ:HUMA) with a Overweight and lowers the pr

This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
benzinga.com
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR

benzinga.com
Benchmark Downgrades Humacyte to Speculative Buy, Lowers Price Target to $1

Benchmark analyst Bruce D. Jackson downgrades Humacyte (NASDAQ:HUMA) from Buy to Speculative Buy

benzinga.com
Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $1

Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and lowers

benzinga.com
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

benzinga.com
BTIG Maintains Buy on Humacyte, Lowers Price Target to $3

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Earnings Scheduled For March 27, 2026
benzinga.com
Earnings Scheduled For March 27, 2026

benzinga.com
Humacyte Commences $20M Offering Of 25M Common Stock

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universa

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session